International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 123-129
CD25 Expression is Associated with Autoimmunity in Patients with CLL

Hacer Berna AFACAN OZTURK1, Abdulkerim YILDIZ1, Murat ALBAYRAK1, Cigdem PALA1, Senem MARAL1, Mesude FALAY2

1University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Hematology, Ankara, TURKEY
2University of Health Sciences, Numune Training and Research Hospital, Department of Hematology, Ankara, TURKEY

Keywords: CD25, Chronic Lymphocytic Leukemia, Autoimmunity, Flow cytometry
It has been shown that CD25 is expressed more in Chronic Lymphocytic Leukemia (CLL) cases. However, there is conflicting data as to its prognostic significance. The aim of this study was to examine the prognostic significance of CD25 in cases in our centre. A retrospective examination was made of hospital records and flow cytometry results at the time of diagnosis of 160 patients diagnosed with CLL in our clinic between June 2009 and April 2018. An analysis of cases with and without CD25 cell surface expression for overall survival and time to treatment revealed no significant difference between the two groups in respect of both parameters (Graphic 1, p> 0.05 and Graphic 2, p> 0.05). Autoimmune cytopenia was determined to be significantly more common in the CD25-negative group. CD25 was seen to have no prognostic significance in CLL. However, a significantly increased rate of autoimmune cytopenia was determined in cases with CD25 negativity. Since this study is the first to demonstrate the relationship between CD25 expression and autoimmune cytopenia in patients with CLL, it may be of guidance for future studies on the same subject and may draw the attention of clinicians to this in clinical practice.